Geron appoints Gaurav Aggarwal, M.D. to its Board of Directors

GERON CORP

Dr. Aggarwal appointed as Class III director effective Nov. 26, 2023; term expires at 2026 annual meeting.
Board determined Aggarwal independent under Nasdaq rules; he brings 20+ years life sciences investing experience.
Received initial option for 200,000 shares at $1.97/share, vesting in three equal annual installments.
Eligible for annual cash retainer of $42,500 and annual option grants of 125,000 shares starting in 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gaurav Aggarwal

Director

GERN · GERON CORP

Effective: 2023-11-26
Filed: November 28, 2023, 6:59 PM ET

appointed Gaurav Aggarwal, M.D. to the Board, effective immediately, as a Class III Board member with a term expiring at the Company’s 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gaurav Aggarwal was appointed as Director at GERON CORP.

Action: appointed
Role: Director

Exact text from the filing

appointed Gaurav Aggarwal, M.D. to the Board, effective immediately, as a Class III Board member with a term expiring at the Company’s 2026 annual meeting of stockholders.

View on SEC.gov

GERON CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-066396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.